New guidance strongly recommends COVID-19 vaccination for immunocompromised patients for the upcoming 2025-2026 respiratory virus season. These individuals face increased risk of severe COVID-19 outcomes, and vaccine protection can be less durable.
The updated guidelines cover patients with hematologic malignancy, primary immunodeficiency, autoimmune disease on immunosuppressive medications, severe HIV, solid organ transplant recipients, hematopoietic cell transplantation, CAR-T therapy, and those receiving chemotherapy.
Evidence review indicates COVID-19 vaccination is associated with fewer hospitalizations, reduced critical illness, and mortality in this vulnerable group. However, effectiveness varies due to population differences, vaccine products, circulating variants, and time since vaccination.
A strong recommendation is issued for age-appropriate 2025-2026 COVID-19 vaccination for all immunocompromised individuals aged six months and older. Timing should be individualized based on treatment regimens, clinical status, and local transmission.
Beyond vaccination, the guidance stresses layered protection, including ensuring close contacts are vaccinated and maintaining timely access to antiviral treatments.